CRISPR Therapeutics CRSP Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's deferred revenue?
- CRISPR Therapeutics (CRSP) reported deferred revenue of $15.34M in Q1 2026.
- How has CRISPR Therapeutics's deferred revenue changed year-over-year?
- CRISPR Therapeutics's deferred revenue increased by 407.9% year-over-year, from $3.02M to $15.34M.
- What is the long-term trend for CRISPR Therapeutics's deferred revenue?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's deferred revenue has grown at a 46.5% compound annual growth rate (CAGR), from $2.34M to $15.77M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.